Previous 10 |
home / stock / hls:cc / hls:cc news
HLS Therapeutics to Present at the 2022 Jefferies Healthcare Conference Canada NewsWire TORONTO , June 1, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular...
HLS Therapeutics Executive Chairman and Co-Founder Bill Wells to Retire Canada NewsWire Co-Founder and Director Greg Gubitz appointed Chair of the Board of HLS TORONTO , May 24, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (...
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec Canada NewsWire Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular disease Private drug plan...
HLS Therapeutics Announces Q1 Fiscal 2022 Financial Results Canada NewsWire Q1 2022 revenue of $14.6 million , Adjusted EBITDA of $6.3 million and cash from operations of $5.8 million . Vascepa® prescriptions grew 12% sequentially and 111% ye...
HLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , April 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2022 financial results on ...
HLS Therapeutics completes negotiations with pCPA for Vascepa® Canada NewsWire Enters into Letter of Intent (LOI) that paves the way for product listing agreements for Vascepa with all of Canada's provinces and territories. Public market access is ex...
HLS Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference HLS Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO , April 25, 2022 /CNW/ - HLS Therapeuti...
HLS Therapeutics Announces Q4 and Fiscal 2021 Financial Results Canada NewsWire Q4 2021 revenue of $15.7 million , Adjusted EBITDA of $6.2 million and cash from operations of $4.0 million 2021 revenue of $60.0 million , Adjusted EBITDA of $2...
News, Short Squeeze, Breakout and More Instantly...
HLS Therapeutics Inc. Company Name:
HLS:CC Stock Symbol:
TSXC Market:
HLS Therapeutics Inc. Website:
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust Canada NewsWire Total consideration of up to $45.75 million , which consists of upfront cash, sales-based milestone payments and DRI Healthcare's assumption of future mi...
A look at the top 10 most actives in Canada BlackBerry Limited (BB) rose 10.5% to $3.36 on volume of 12,209,225 shares Solstice Gold Corp. (SGC) fell 33.3% to $0.02 on volume of 11,588,936 shares HIGH INTEREST SAVINGS ACCOUNT FUND (HISA) fell 0.3% to $50.01 on volume of 10,628,355 shares ...
Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...